Literature DB >> 29029884

Identification of ATIC as a Novel Target for Chemoradiosensitization.

Xiangfei Liu1, Uma Devi Paila2, Sharon N Teraoka1, Jocyndra A Wright1, Xin Huang1, Aaron R Quinlan3, Richard A Gatti4, Patrick Concannon5.   

Abstract

PURPOSE: Mutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functional studies were performed to determine whether ATIC inhibition was radiosensitizing and, if so, to elucidate the mechanism of this effect and determine whether small molecule inhibitors of ATIC could act as effective radiosensitizing agents. METHODS AND MATERIALS: Both small interfering RNA knockdown and small molecule inhibitors were used to inactivate ATIC in cell culture. Clonogenic survival assays, the neutral comet assay, and γH2AX staining were used to assess the effects of ATIC inhibition or depletion on cellular DNA damage responses.
RESULTS: Depletion of ATIC or inhibition of its transformylase activity significantly reduced the surviving fraction of cells in clonogenic survival assays in multiple cancer cell lines. In the absence of ionizing radiation exposure, ATIC knockdown or chemical inhibition activated cell cycle checkpoints, shifting cells to the more radiosensitive G2/M phase of the cell cycle, and depleted cellular adenosine triphosphate but did not result in detectable DNA damage. Cells in which ATIC was knocked down or inhibited and then treated with ionizing radiation displayed increased numbers of DNA double-strand breaks and a delay in the repair of those breaks relative to irradiated, but otherwise untreated, controls. Supplementation of culture media with exogenous adenosine triphosphate ameliorated the DNA repair phenotypes.
CONCLUSIONS: These findings implicate ATIC as an effective, and previously unrecognized, target for chemoradiosensitization and, more broadly, suggest that purine levels in cells might have an underappreciated role in modulating the efficiency of DNA damage responses that could be exploited in radiosensitizing strategies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29029884      PMCID: PMC5736427          DOI: 10.1016/j.ijrobp.2017.08.033

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  44 in total

1.  Genetically selected cyclic-peptide inhibitors of AICAR transformylase homodimerization.

Authors:  Ali Tavassoli; Stephen J Benkovic
Journal:  Angew Chem Int Ed Engl       Date:  2005-04-29       Impact factor: 15.336

2.  Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors.

Authors:  Chenglong Li; Lan Xu; Dennis W Wolan; Ian A Wilson; Arthur J Olson
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

Review 3.  Clinical radiation sensitivity with DNA repair disorders: an overview.

Authors:  Julianne M Pollard; Richard A Gatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

4.  Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome.

Authors:  R Varon; C Vissinga; M Platzer; K M Cerosaletti; K H Chrzanowska; K Saar; G Beckmann; E Seemanová; P R Cooper; N J Nowak; M Stumm; C M Weemaes; R A Gatti; R K Wilson; M Digweed; A Rosenthal; K Sperling; P Concannon; A Reis
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

5.  A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer.

Authors:  N K Gupta; R C Pointon; P M Wilkinson
Journal:  Clin Radiol       Date:  1987-11       Impact factor: 2.350

6.  Comprehensive profiling of radiosensitive human cell lines with DNA damage response assays identifies the neutral comet assay as a potential surrogate for clonogenic survival.

Authors:  Shareef A Nahas; Robert Davies; Francesca Fike; Kotoka Nakamura; Liutao Du; Refik Kayali; Nathan T Martin; Patrick Concannon; Richard A Gatti
Journal:  Radiat Res       Date:  2011-09-30       Impact factor: 2.841

7.  Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression.

Authors:  Toran Sanli; Caiqiong Liu; Ayesha Rashid; Sarah N Hopmans; Evangelia Tsiani; Carrie Schultz; Thomas Farrell; Gurmit Singh; James Wright; Theodoros Tsakiridis
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

8.  Stimulation of rat liver AMP-activated protein kinase by AMP analogues.

Authors:  N Henin; M F Vincent; G Van den Berghe
Journal:  Biochim Biophys Acta       Date:  1996-06-04

9.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

10.  AMPK Activation via Modulation of De Novo Purine Biosynthesis with an Inhibitor of ATIC Homodimerization.

Authors:  Daniel J Asby; Francesco Cuda; Maxime Beyaert; Franchesca D Houghton; Felino R Cagampang; Ali Tavassoli
Journal:  Chem Biol       Date:  2015-07-02
View more
  9 in total

1.  Construction of a prognosis-predicting model based on autophagy-related genes for hepatocellular carcinoma (HCC) patients.

Authors:  Yayun Zhu; Ru Wang; Wanbin Chen; Qiuyu Chen; Jian Zhou
Journal:  Aging (Albany NY)       Date:  2020-07-18       Impact factor: 5.682

2.  Survival analysis and functional annotation of long non-coding RNAs in lung adenocarcinoma.

Authors:  Abbas Salavaty; Zahra Rezvani; Ali Najafi
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

3.  Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma.

Authors:  Wen-Jing Su; Pei-Zhi Lu; Yong Wu; Kumari Kalpana; Cheng-Kun Yang; Guo-Dong Lu
Journal:  Front Oncol       Date:  2021-01-14       Impact factor: 6.244

4.  A Novel Autophagy-Related Prognostic Risk Model and a Nomogram for Survival Prediction of Oral Cancer Patients.

Authors:  Hongjun Fei; Xiongming Chen
Journal:  Biomed Res Int       Date:  2022-01-06       Impact factor: 3.411

5.  ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival.

Authors:  Hao Zhang; Peng Xia; Jie Liu; Zhang Chen; Weijie Ma; Yufeng Yuan
Journal:  Int J Biol Sci       Date:  2021-10-25       Impact factor: 6.580

6.  Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma.

Authors:  Minjun Du; Yicheng Liang; Zixu Liu; Xingkai Li; Mei Liang; Boxuan Zhou; Yushun Gao
Journal:  Front Oncol       Date:  2021-09-28       Impact factor: 6.244

7.  A Novel Metabolism-Related Gene Signature for Predicting the Prognosis of HBV-Infected Hepatocellular Carcinoma.

Authors:  Zhenfu Gao; Jingyun Chen; Yebin Zhou; Pan Deng; Lu Sun; Jun Qi; Ping Zhang
Journal:  J Oncol       Date:  2022-08-28       Impact factor: 4.501

8.  PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer.

Authors:  Sumit Agarwal; Balabhadrapatruni V S K Chakravarthi; Michael Behring; Hyung-Gyoon Kim; Darshan S Chandrashekar; Nirzari Gupta; Prachi Bajpai; Amr Elkholy; Sai A H Balasubramanya; Cherlene Hardy; Sameer Al Diffalha; Sooryanarayana Varambally; Upender Manne
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

9.  Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients.

Authors:  Xingxing Huo; Jian Qi; Kaiquan Huang; Su Bu; Wei Yao; Ying Chen; Jinfu Nie
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.